Similar articles

• Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo.

  Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, Baudrexel S, Diederich NJ, Heiss WD, Hilker R. Klein JC, et al. Neurology. 2010 Mar 16;74(11):885-92. doi: 10.1212/WNL.0b013e3181d55f61. Epub 2010 Feb 24. Neurology. 2010. PMID: 20181924
• Imaging the dopaminergic system in suspected parkinsonism, drug induced movement disorders, and Lewy body dementia.

  Kemp PM. Kemp PM. Nucl Med Commun. 2005 Feb;26(2):87-96. doi: 10.1097/00006231-200502000-00002. Nucl Med Commun. 2005. PMID: 15657499 Review.
• Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography.

  Brooks DJ. Brooks DJ. Mov Disord. 2009;24 Suppl 2:S742-7. doi: 10.1002/mds.22581. Mov Disord. 2009. PMID: 19877240 Review.
• Functional imaging in Parkinson's disease and dementia with Lewy bodies.

  Colloby S, O'Brien J. Colloby S, et al. J Geriatr Psychiatry Neurol. 2004 Sep;17(3):158-63. doi: 10.1177/0891988704267468. J Geriatr Psychiatry Neurol. 2004. PMID: 15312279 Review.
• Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease.

  Suzuki M, Kurita A, Hashimoto M, Fukumitsu N, Abo M, Ito Y, Urashima M, Inoue K. Suzuki M, et al. J Neurol Sci. 2006 Jan 15;240(1-2):15-9. doi: 10.1016/j.jns.2005.08.011. Epub 2005 Sep 29. J Neurol Sci. 2006. PMID: 16199056